Trikafta (Elexacaftor / Tezacaftor / Ivacaftor)

Brand names:Trikafta, Kaftrio
Medication

What people taking Trikafta (Elexacaftor / Tezacaftor / Ivacaftor) report

Every report comes from a Lived member, sent anonymously.

Have you tried Trikafta (Elexacaftor / Tezacaftor / Ivacaftor) for Cystic Fibrosis?

NameHow it went

About Trikafta (Elexacaftor / Tezacaftor / Ivacaftor)

What It's For

Trikafta is a prescription medicine for cystic fibrosis (CF), the inherited condition in which thick, sticky mucus damages the lungs and affects the pancreas, digestive system and other organs. It combines three drugs, elexacaftor, tezacaftor and ivacaftor, and belongs to a group called CFTR modulators, which target the faulty CFTR (cystic fibrosis transmembrane conductance regulator) protein behind CF rather than its individual symptoms. In Europe and the UK the same combination is sold as Kaftrio, taken together with separate ivacaftor tablets. In the US, Trikafta is approved for people aged 2 and older who have a clinical diagnosis of CF and at least one CFTR gene variant that either responds to the drug or still produces some CFTR protein. That includes F508del, the most common CF variant, carried by up to 90% of people with CF, as well as hundreds of rarer variants. Genetic testing confirms eligibility, but a qualifying variant is not enough on its own: the person must also have CF. People whose variants produce no CFTR protein at all fall outside the approval. Other CFTR modulators include Kalydeco (ivacaftor alone), approved from 1 month of age for specific responsive variants, and Alyftrek (vanzacaftor, tezacaftor and deutivacaftor), a newer once-daily triple combination for ages 6 and older. The older two-drug combinations, Orkambi and Symdeko, give smaller benefits, and a Cochrane review no longer considers them standard therapy, although they may still be used when a triple combination is not suitable, for example because of age or side effects.

How It Works

CF happens when both copies of the CFTR gene carry a harmful change. The gene's protein, also called CFTR, sits on the surface of cells lining the airways, gut, pancreas and sweat glands, where it works as a channel that moves chloride (part of ordinary salt) across the cell surface. Water follows salt, so a working channel keeps mucus moist enough to clear. When CFTR is missing or faulty, mucus turns thick and sticky, blocks small airways and ducts, and gives bacteria a place to grow. Sweat also becomes unusually salty, which is why a sweat test is used to diagnose CF. Trikafta's three ingredients fix the faulty protein in two complementary ways. Elexacaftor and tezacaftor are correctors: they help a misshapen protein, such as the one made from F508del, fold properly and reach the cell surface, so more channels arrive where they are needed. Ivacaftor is a potentiator: it helps channels that are already at the surface open more often. Together they increase both the number of CFTR channels and how well they work. Because this acts on the underlying protein, the effects can reach the lungs, digestion, weight and sweat at the same time. It does not change the gene itself, which is why Trikafta is a long-term daily treatment rather than a cure.

Dosage & Administration

Trikafta is taken twice a day, about 12 hours apart. For people 6 and older, the morning dose is two combination tablets (elexacaftor, tezacaftor and ivacaftor) and the evening dose is one tablet of ivacaftor alone. The tablets are swallowed whole. Children aged 2 to under 6 take oral granules instead: one packet in the morning and a different packet in the evening, each mixed with a teaspoon of soft food or liquid at or below room temperature, such as yogurt, applesauce or milk, and finished within an hour. The strength depends on age and weight, so the prescription sets the exact product. Every dose should be taken with food that contains fat, such as eggs, butter, peanut butter, cheese, nuts, whole milk or meat, because the medicine is best absorbed that way. A typical CF diet usually provides enough fat, but a dose taken with only fruit or a fat-free snack is absorbed less well. If a dose is missed and 6 hours or less have passed, take it as soon as possible with fat-containing food. If more than 6 hours have passed, take a missed morning dose as soon as possible and skip that evening's dose; skip a missed evening dose entirely. The morning and evening doses should never be taken at the same time. People with moderate liver disease, or who need certain interacting medicines, may be given a reduced schedule by the prescriber.

Side Effects

The most common side effects are headache, cold-like symptoms such as a stuffy or runny nose and sinus infections, stomach pain, diarrhea, constipation and rash. Rash is more common in women and girls, and hormonal birth control may play a part; if a rash appears in someone using it, the prescriber may pause one or both and restart them one at a time. Blood tests can also show raised liver enzymes or raised creatine phosphokinase, a muscle enzyme. These are usually found on routine testing rather than felt. Liver injury is the most important serious risk. Yellowing of the skin or the whites of the eyes, pain under the right ribs, ongoing nausea or vomiting, unusual confusion or a swelling belly mean pausing the medicine and calling the prescriber right away. New or worsening anxiety, low mood, trouble sleeping or suicidal thoughts have been reported, often within the first three months and in adults and children with no history of these problems. Changes in mood, thinking or behavior should be reported to the prescriber right away rather than waited out. An unusual headache, blurred or double vision, or loss of vision can signal raised pressure around the brain (intracranial hypertension), which has been reported with Trikafta. Contact the care team right away if these occur. High vitamin A levels may increase this risk. Swelling of the face or lips, chest tightness or wheezing after a dose can be a serious allergic reaction. Stop the medicine and get emergency care. Children starting Trikafta should have an eye exam at the start and during treatment, because cataracts (clouding of the lens) have been reported in children taking ivacaftor-containing medicines.

Interactions & Warnings

Trikafta carries a boxed warning, the US Food and Drug Administration's most prominent safety warning, for liver injury. Serious liver damage, including liver failure that led to transplantation or death, has occurred in people with and without earlier liver problems, from the first month of treatment up to 15 months after starting. For that reason, liver blood tests are done before the first dose, every month for the first 6 months, every 3 months for the next year and at least once a year after that, with more frequent checks for people who already have liver disease. Trikafta should not be used with severe liver disease and is generally avoided with moderate liver disease unless the benefit clearly outweighs the risk. The body breaks down all three ingredients with a liver enzyme called CYP3A, so medicines that speed up or slow down that enzyme change how much drug reaches the blood. Strong enzyme speeders can make Trikafta less effective and should be avoided. They include rifampin and rifabutin (antibiotics used mainly for tuberculosis and related infections), the seizure medicines carbamazepine, phenytoin and phenobarbital, and the herbal supplement St. John's wort. Medicines that slow the enzyme raise drug levels, including the antifungals itraconazole, ketoconazole, posaconazole, voriconazole and fluconazole and the antibiotics clarithromycin and erythromycin. These can still be used, but the prescriber will reduce the Trikafta schedule while they are taken. Grapefruit and grapefruit juice should be avoided for the same reason. Trikafta can also raise levels of some other medicines. People taking warfarin need closer INR (international normalized ratio) checks, the blood test that shows how long blood takes to clot. Transplant medicines such as tacrolimus and cyclosporine, the heart medicine digoxin, some statins and some diabetes pills also call for caution and monitoring. Tell the CF team and pharmacist about every prescription, supplement and herbal product. Information on pregnancy is still limited. Studies so far have not clearly linked use during pregnancy to serious harm to the baby, but long-term effects in exposed children are unknown, and there is not enough evidence on safety during breastfeeding. Pregnancy rates among women with CF have more than doubled since Trikafta was approved, and many of those pregnancies were unplanned, so contraception and pregnancy plans are worth discussing with the CF team early.

What to Expect

Many people notice changes quickly. In the main trial, in people 12 and older with one F508del variant, lung function had already improved at the first check after two weeks. Over 24 weeks, FEV1 rose by about 14 percentage points more than with placebo. FEV1 is the amount of air a person can blow out in one second, and it is reported as a percentage of the value expected for someone of the same age, sex, height and weight. The average starting value in that trial was about 61%, so a 14-point gain is a large change. Lung flare-ups needing a change in antibiotics (pulmonary exacerbations) happened about 63% less often, people reported fewer breathing symptoms such as cough and mucus, weight rose, and the salt level in sweat fell sharply, a sign that the CFTR protein was working better. Response still varies between people and between variants. The pivotal trials mostly enrolled people 12 and older whose lung function was between 40% and 90% of expected, and Trikafta has been available only since 2019, so its effect on lifespan over decades is not yet known. There is no cure for CF, and Trikafta is meant to be taken long term. It usually works alongside the rest of CF care, such as airway clearance, nutrition, exercise and treatment of infections, rather than replacing it. Some people whose lungs are doing well ask about dropping daily nebulized treatments. In one trial of people with well-preserved lung function on Trikafta, stopping hypertonic saline (a strong salt-water mist) or dornase alfa (an inhaled mucus-thinning medicine) for six weeks did not worsen lung function, but longer-term effects and effects in people with lower lung function are less clear, so any change should be planned with the CF team. Follow-up includes the liver test schedule, regular CF clinic visits with lung function tests, and eye exams for children.

Questions to Ask Your Doctor

  1. 1.Do my CFTR variants make me eligible for Trikafta, and would Alyftrek or another modulator suit me better?
  2. 2.What changes in lung function, weight or symptoms should we look for, and when will we measure them?
  3. 3.How will my liver tests be scheduled, and what results would lead us to pause treatment?
  4. 4.Which of my current medicines, supplements or CF treatments need to change, and could any daily treatments be reduced once I am stable?
  5. 5.How does Trikafta fit with my plans for contraception, pregnancy or breastfeeding?

Last reviewed • Oct 2026

Educational content, not medical advice.